查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1866216

全球季節性情緒障礙治療市場成長、規模和趨勢分析（治療方法、疾病類型和最終用戶分類）—區域展望、競爭策略和細分市場預測（至 2034 年）

Global Seasonal Affective Disorder Therapeutics Market Growth, Size, Trends Analysis - By Treatment Type, By Disorder Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 259 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2034 年，全球季節性情感障礙治療市場規模將達到 13.3853 億美元，複合年成長率為 4.98%。

季節性情感障礙（SAD）是一種憂鬱症，多發於特定季節，尤其是在秋季和冬季，此時自然光照減少。治療方法包括光療、抗憂鬱症、心理治療和生活方式調整，所有這些方法都旨在改善情緒和精力水平。近年來，醫療產業致力於開發創新且以患者為中心的治療方法，以提高治療的可及性和有效性。

阻礙因素：儘管需求不斷成長，季節性情感障礙的廣泛治療仍面臨許多障礙。抗憂鬱症的副作用和黑框警告會降低患者的依從性，並削弱長期療效。中低收入國家對此疾病的認知度低和診斷不足也阻礙了患者快速獲得治療。支付者對使用迷幻藥和氯胺酮等藥物的非標籤藥物治療診所的限制進一步阻礙了替代療法的廣泛應用。最後，用於製造LED燈箱的稀土元素的供應不穩定，威脅著生產的穩定性和市場供應。

本報告調查了全球季節性情感障礙治療市場，並提供了市場概況、市場影響因素和市場機會分析、市場規模趨勢和預測、依各個區隔市場、地區/主要國家進行的詳細分析、競爭格局以及主要企業的概況。

目錄

第1章 引言

第2章調查方法

第3章摘要整理

第4章 市場動態

  • 促進因素、阻礙因素、機會與挑戰分析

第5章 市場變數與展望

  • SWOT分析
  • PESTEL 分析
  • 波特五力分析
  • 熱圖分析

第6章 競爭情勢

  • 製造地、銷售區域和產品類型的分佈
  • 併購、合作、產品發布與協作

7. 全球季節性情感障礙治療市場（依治療類型分類）

  • 藥物
    • 選擇性血清素再回收抑制劑（SSRIs）
    • 去甲腎上腺素多巴胺再回收抑制劑（NDRIs）
    • 單胺氧化酵素抑制劑（MAOIs）
    • 其他
  • 治療
    • 光療
    • 心理治療

8. 全球季節性情感障礙治療市場（依疾病類型分類）

  • 秋季和冬季季節性情感障礙
  • 春夏季節性情感障礙

9. 全球季節性情感障礙治療市場（以最終用戶分類）

  • 醫院
  • 專科診所
  • 居家照護
  • 其他

第10章 全球季節性情感性疾患治療市場

  • 全球市場規模和市場佔有率

11. 全球季節性情感障礙治療市場（依地區分類）

  • 亞太地區
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亞
    • 其他
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美國
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他

第12章 公司概況

  • AbbVie
  • Amen Clinics
  • Bausch Health Companies
  • Cleveland Clinic
  • Eli Lilly and Company
  • GlaxoSmithKlinz
  • Henry Schein
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Mayo Clinic
  • Novartis
  • 其他

第13章 結論

第14章簡稱列表

第15章參考鏈接

簡介目錄
Product Code: HLCA25317

Global Seasonal Affective Disorder Therapeutics Market Introduction and Overview

According to SPER market research, 'Global Seasonal Affective Disorder Therapeutics Market Size- By Treatment Type, By Diagnosis Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' states that the Global Seasonal Affective Disorder Therapeutics Market is predicted to reach 1338.53 million by 2034 with a CAGR of 4.98%.

Seasonal Affective Disorder (SAD) is a type of depression that occurs during specific seasons, most notably fall and winter, when natural sunlight is reduced. Light treatment, antidepressant medicines, psychotherapy, and lifestyle changes are all used to treat SAD and improve mood and energy levels. The healthcare and mental health industries are increasingly focusing on creative and patient-friendly techniques to improve treatment accessibility and effectiveness.

Restraints: Despite rising demand, various barriers prevent the widespread use of Seasonal Affective Disorder treatments. Side effects and black-box warnings on antidepressants frequently reduce patient adherence, lowering long-term effectiveness. Low awareness and underdiagnosis in low- and middle-income countries impede prompt treatment access. Furthermore, payor restrictions for off-label psychedelic or ketamine-based clinics limit the expansion of alternate therapy pathways. Another issue comes with LED light boxes, where rare-earth element supply issues jeopardize production stability and availability.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Treatment Type, By Disorder Type, By End User

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered AbbVie, Amen Clinics, Bausch Health Companies, Cleveland Clinic, Eli Lilly and Company, GlaxoSmithKline, Henry Schein, Johnson & Johnson (Janssen Pharmaceuticals), Mayo Clinic, Novartis.

Global Seasonal Affective Disorder Therapeutics Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Medications, Therapy.

By Disorder Type: Based on the Disorder Type, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Fall & winter SAD, Spring & summer SAD.

By End User: Based on the End User, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Hospitals, Specialty clinics, Homecare setting, Other end user.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

1.Introduction

  • 1.1.Scope of the report
  • 1.2.Market segment analysis

2.Research Methodology

  • 2.1.Research data source
    • 2.1.1.Secondary Data
    • 2.1.2.Primary Data
    • 2.1.3.SPERs internal database
    • 2.1.4.Premium insight from KOLs
  • 2.2.Market size estimation
    • 2.2.1.Top-down and Bottom-up approach
  • 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

  • 4.1.Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1.Drivers
    • 4.1.2.Restraints
    • 4.1.3.Opportunities
    • 4.1.4.Challenges

5.Market variable and outlook

  • 5.1.SWOT Analysis
    • 5.1.1.Strengths
    • 5.1.2.Weaknesses
    • 5.1.3.Opportunities
    • 5.1.4.Threats
  • 5.2.PESTEL Analysis
    • 5.2.1.Political Landscape
    • 5.2.2.Economic Landscape
    • 5.2.3.Social Landscape
    • 5.2.4.Technological Landscape
    • 5.2.5.Environmental Landscape
    • 5.2.6.Legal Landscape
  • 5.3.PORTERs Five Forces
    • 5.3.1.Bargaining power of suppliers
    • 5.3.2.Bargaining power of buyers
    • 5.3.3.Threat of Substitute
    • 5.3.4.Threat of new entrant
    • 5.3.5.Competitive rivalry
  • 5.4.Heat Map Analysis

6.Competitive Landscape

  • 6.1.Global Seasonal Affective Disorder Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Seasonal Affective Disorder Therapeutics Market

7.Global Seasonal Affective Disorder Therapeutics Market, By Treatment Type (USD Million) 2021-2034

  • 7.1.Medication
    • 7.1.1.Selective serotonin reuptake inhibitors (SSRI)
    • 7.1.2.Norepinephrine-dopamine reuptake inhibitor (NDRI)
    • 7.1.3.Monoamine oxidase inhibitor (MAOI)
    • 7.1.4.Other drug types
  • 7.2.Therapy
    • 7.2.1.Light therapy
    • 7.2.2.Psychotherapy

8.Global Seasonal Affective Disorder Therapeutics Market, By Disorder Type (USD Million) 2021-2034

  • 8.1.Fall & winter SAD
  • 8.2.Spring & summer SAD

9.Global Seasonal Affective Disorder Therapeutics Market, By End User (USD Million) 2021-2034

  • 9.1.Hospitals
  • 9.2.Specialty clinics
  • 9.3.Homecare setting
  • 9.4.Other end use

10.Global Seasonal Affective Disorder Therapeutics Market, (USD Million) 2021-2034

  • 10.1.Global Seasonal Affective Disorder Therapeutics Market Size and Market Share

11.Global Seasonal Affective Disorder Therapeutics Market, By Region, (USD Million) 2021-2034

  • 11.1.Asia-Pacific
    • 11.1.1.Australia
    • 11.1.2.China
    • 11.1.3.India
    • 11.1.4.Japan
    • 11.1.5.South Korea
    • 11.1.6.Rest of Asia-Pacific
  • 11.2.Europe
    • 11.2.1.France
    • 11.2.2.Germany
    • 11.2.3.Italy
    • 11.2.4.Spain
    • 11.2.5.United Kingdom
    • 11.2.6.Rest of Europe
  • 11.3.Middle East and Africa
    • 11.3.1.Kingdom of Saudi Arabia
    • 11.3.2.United Arab Emirates
    • 11.3.3.Qatar
    • 11.3.4.South Africa
    • 11.3.5.Egypt
    • 11.3.6.Morocco
    • 11.3.7.Nigeria
    • 11.3.8.Rest of Middle-East and Africa
  • 11.4.North America
    • 11.4.1.Canada
    • 11.4.2.Mexico
    • 11.4.3.United States
  • 11.5.Latin America
    • 11.5.1.Argentina
    • 11.5.2.Brazil
    • 11.5.3.Rest of Latin America

12.Company Profile

  • 12.1.AbbVie
    • 12.1.1.Company details
    • 12.1.2.Financial outlook
    • 12.1.3.Product summary
    • 12.1.4.Recent developments
  • 12.2.Amen Clinics
    • 12.2.1.Company details
    • 12.2.2.Financial outlook
    • 12.2.3.Product summary
    • 12.2.4.Recent developments
  • 12.3.Bausch Health Companies
    • 12.3.1.Company details
    • 12.3.2.Financial outlook
    • 12.3.3.Product summary
    • 12.3.4.Recent developments
  • 12.4.Cleveland Clinic
    • 12.4.1.Company details
    • 12.4.2.Financial outlook
    • 12.4.3.Product summary
    • 12.4.4.Recent developments
  • 12.5.Eli Lilly and Company
    • 12.5.1.Company details
    • 12.5.2.Financial outlook
    • 12.5.3.Product summary
    • 12.5.4.Recent developments
  • 12.6.GlaxoSmithKlinz
    • 12.6.1.Company details
    • 12.6.2.Financial outlook
    • 12.6.3.Product summary
    • 12.6.4.Recent developments
  • 12.7.Henry Schein
    • 12.7.1.Company details
    • 12.7.2.Financial outlook
    • 12.7.3.Product summary
    • 12.7.4.Recent developments
  • 12.8.Johnson & Johnson (Janssen Pharmaceuticals)
    • 12.8.1.Company details
    • 12.8.2.Financial outlook
    • 12.8.3.Product summary
    • 12.8.4.Recent developments
  • 12.9.Mayo Clinic
    • 12.9.1.Company details
    • 12.9.2.Financial outlook
    • 12.9.3.Product summary
    • 12.9.4.Recent developments
  • 12.10.Novartis
    • 12.10.1.Company details
    • 12.10.2.Financial outlook
    • 12.10.3.Product summary
    • 12.10.4.Recent developments
  • 12.11.Others

13.Conclusion

14.List of Abbreviations

15.Reference Links